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Summary Background: While autonomic neuropathy has been reported in chroni-
cally hypoxaemic patients of chronic obstructive pulmonary disease (COPD), whether
it also occurs in patients with milder disease and in those without chronic
hypoxaemia has not been explored.
Methodology: Lung function measurements including spirometry and transfer
factor for carbon monoxide, mean pulmonary artery pressure estimation by color-
doppler echocardiography and arterial blood gas analysis were carried out in 56
patients with COPD and 11 age-matched controls. Autonomic function was assessed
by tests of cardiovascular reflexes and expressed as valsalva ratio, 30:15 ratio, IE
difference and the blood pressure response to postural change.
Results: Among patients, majority of the test responses were in the abnormal or
borderline range compared to more than 90% of test responses in the normal or
borderline range among normals. Almost 50% of patients had definite neuropathy as
compared to none in normals. Although, the autonomic neuropathy tended to be
observed more often in patients with moderate and severe COPD, it was also found in
a fair proportion of patients with mild COPD. Similarly, while it was more prevalent
in patients with hypoxaemia, it was also found to occur in those without
hypoxaemia. The responses to tests of autonomic function had weak relationships
with FEV1% predicted and PaO2.
Conclusions: Cardiovascular autonomic neuropathy is common in COPD and is
found even in early stages of the disease.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Chronic hypoxaemia has been postulated as a
mechanism for the development of peripheral
neuropathy1 in diabetes mellitus. An increased
incidence of peripheral neuropathy has also been
observed in chronic obstructive pulmonary disease
(COPD) and may be related to chronic hypoxae-
mia.2 Indeed, electrophysiological abnormalities
have been reported to be much more common 3,4
than clinically manifest neuropathy.
Autonomic neuropathy is another well-recog-
nized complication of diabetes mellitus. It is
important as it has been implicated in sudden
cardiorespiratory arrest.5 Unlike diabetes mellitus,
the occurrence of autonomic neuropathy has
received much less attention in COPD. It was first
reported in chronically hypoxaemic patients by
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Stewart et al.6 in 1991. They observed definite
autonomic dysfunction in 35% and evidence of early
autonomic neuropathy in another 47% of patients
and it was attributed to chronic hypoxaemia. Its
significance remains undefined as there were no
clinical manifestations.
Findings of autonomic neuropathy unresponsive
to short-term oxygen treatment were reported
later by Hjalmarsen et al.7 This suggests that either
the neuropathy may not relate to the presence of
hypoxaemia or may be an irreversible process. It is
also possible that the autonomic neuropathy in
COPD is not a complication but an independent
process that runs in parallel with other physiologi-
cal changes. It implies that it should be possible to
detect its presence even in milder cases of COPD.
This has not been explored earlier. We therefore
carried out the present study to assess autonomic
cardiovascular function in patients with a wider
spectrum of clinical severity, from mild-to-severe.
In addition to the severity of airways obstruction
and abnormalities of arterial blood gases, its
relationship with echocardiographically measured
mean pulmonary artery pressure (MPAP), another
commonly affected physiological parameter in
COPD, was also investigated.
Methods
Fifty-six patients, all males and diagnosed as having
COPD were included in this prospective study
carried out in the outpatient setting in a tertiary
referral hospital, Vallabhbhai Patel Chest Institute,
Delhi. Eleven age-matched healthy non-smoker
subjects served as the controls. The study was
approved by the Institutional Review Committee.
Informed consent was taken.
The diagnosis of COPD was based on the criteria
of the British Thoracic Society8 and established by a
history of smoking greater than 20 pack-years,
cough with expectoration accompanied by progres-
sively increasing dyspnoea on exertion. Asthma was
excluded clinically. Only stable patients requiring
no change in their medication in the previous 4
weeks and not having had an acute exacerbation in
that period were included. The inclusion criteria
included an FEV1/FVC ratio of less than 70% and a
post-bronchodilator increase in FEV1 of less than
12% and 200ml from the initial value. The severity
of COPD was categorized on the basis of FEV1%
predicted as per the British Thoracic Society
Criteria8: mild (above 60%), moderate (40–59.9%)
and severe (less than 40%). Patients with clinical
cor pulmonale, congenital, rheumatic or any
valvular heart disease, systemic hypertension,
coronary artery disease and any other past or
concurrent pulmonary disease, diabetes mellitus,
renal failure, carcinoma, connective tissue disorder
and liver disease were excluded clinically and by
biochemical tests where relevant. None of the
patients consumed alcohol on a regular basis or had
any dietary deficiency of vitamins (B group) or had
any disease such as malabsorption that could cause
vitamin deficiency. These patients were not on any
medication other than that required for control of
COPD. These drugs included inhaled bronchodila-
tors (salbutamol and ipratropium bromide) and
corticosteroids (budesonide, beclomethasone or
fluticasone).
The investigations were carried out in the
morning between 10AM and 12 noon. The patients
were asked not to take bronchodilators 12 h before
the tests. Inhaled corticosteroids were allowed in
the same dosage as being already taken. A light
breakfast was permitted at least 2 h before the
tests.
Spirometry was performed on dry, rolling-seal
spirometer of the Transfer Test C model lung
function machine (P.K. Morgan, Kent, UK). Max-
imal expiratory flow volume (MEFV) curves were
obtained. Three acceptable and at least two
reproducible curves were obtained in each sub-
ject. The highest FEV1 obtained was recorded.
Reference equations for north Indian adults were
used to calculate the percent-predicted values.9
Single breath carbon monoxide diffusion capacity
(DLCOSB) was measured on the same apparatus
and corrected for alveolar volume to obtain
transfer factor ðTLCOÞ: Arterial blood gas analysis
was carried out on a sample drawn from the
radial artery in a heparinzed glass syringe and
measured in Instrumentation Laboratory machine
(Model 1312). Echocardiographic assessment was
done by using all standard echocardiographic
windows (parasternal long-axis view, parasternal
short-axis view, apical four chamber view, sub-
coastal view). Following M-mode and 2-D assess-
ment of morphology, color flow mapping was
done to identify the pulmonary and tricupsid
regurgitant jets. A pulsed doppler study was next
applied to confirm and localize the above regur-
gitant jets and then, continuous wave doppler
study was done to record their maximum velocity.
Mean pulmonary artery pressure (MPAP) was
calculated from the right-ventricular outflow
tract flow acceleration time using the Mahan’s
equation.10
Autonomic function was assessed by tests of
cardiovascular reflexes.11 These are simple, reli-
able, non-invasive and reproducible. The tests
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were carried out in a quiet and comfortable room
with the temperature maintained around 25–281C.
The heart rate responses were obtained from a
standard lead II strip recording on an ECG machine
while the blood pressure (BP) was measured using a
mercury sphygmomanometer. The heart rate re-
sponses test the parasympathetic function while
the BP response tests the sympathetic function.
The following test were done:
Heart rate response to valsalva maneuver
The patient rested for 5min in a sitting position.
Then, after a moderate inspiration, the patient
performed a Valsalva maneuver by blowing into a
mouthpiece connected to a modified sphygmoman-
ometer with a column-holding pressure of 40mm of
Hg for 15 s during which a continuous ECG was
recorded. The patient then breathed normally for a
minute. The heart rate was recorded as inverse of
the RR interval. The results were expressed as
Valsalva ratio, which is ratio of the longest RR
interval after release from the maneuver to the
shortest RR interval during the maneuver. The
maneuver was performed three times. The mean of
three values was taken as the final value. It was
ensured that maximal inspiration was not taken as
that lowers the values. A value o1:10 was taken as
abnormal, 1.11–1.12 as borderline and X1:13 as
normal.11
Heart rate variation during deep breathing
The patient was seated and performed six deep
breaths over a 1-min period. The maximum and
minimum RR interval during each breathing cycle
were measured and converted to beats per minute.
The result was expressed as the difference of heart
rate during inspiration and expiration (I–E differ-
ence). Normally, heart rate falls during expiration.
Patients with an autonomic neuropathy lose this
variability. An I–E difference o11 beats/min was
taken as abnormal, 11–14 as borderline andX15 as
normal.11
Heart rate response to postural change
The patient was asked to lie supine for 3min. Then
he was then asked to rise rapidly and unaided to a
standing position. In a normal response, the heart
rate is maximal at the 15th beat and minimum
around the 30th beat. The shortest RR interval at
or around the 15th beat and longest RR interval
around the 30th beat after starting to stand was
measured. The heart rate response was expressed
as the 30:15 ratio. Patients with autonomic neuro-
pathy have a heart rate that continues to rise
through this observed time. An average of three
readings was taken. A value o1.01 was taken as
abnormal, 1.01–1.03 as borderline and X1.04 as
normal.11
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Table 1 Patient characteristics.
Mild COPD ðn ¼ 13Þ Moderate COPD ðn ¼ 17Þ Severe COPD ðn ¼ 26Þ
Age (years)ns 54.31710.34 60.2977.79 58.27710.53
BMI* 24.247 3.46 23.737 5.21 20.417 4.52
FEV1% predicted
*** 78.99714.96 50.1975.61 28.9175.34
PaO2 (mmHg)
* 80.23711.53 76.71710.79 71.0079.41
PaCO2 (mmHg)
** 39.5371.56 41.1374.15 43.6274.04
MPAP (mmHg)*,w 23.44710.56 33.6478.64 35.16711.76
ANOVA: *Po0.05; **Po0.01; ***Po0.001; ns: not significant, P40.05; wn¼ 9, 11, 19 for mild, moderate and severe COPD,
respectively.
Table 2 Frequency of different types of responses to tests of autonomic function.
Test COPD patients Normal subjects
Normal Borderline Abnormal Normal Borderline Abnormal
Valsalva ratio 22 (39.3) 8 (14.3) 26 (46.4) 10 (90.9) 1 (9.1) 0 (0)
IE difference 13 (23.2) 11 (19.6) 32 (57.1) 4 (36.4) 5 (45.5) 2 (18.2)
30:15 ratio 36 (64.3) 2 (3.6) 18 (32.1) 8 (72.7) 2 (18.2) 1 (9.1)
BP response to posture change 12 (21.4) 24 (42.9) 20 (35.7) 3 (27.3) 7 (63.6) 1 (9.1)
Figures in parenthesis are row percentages.
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BP response to postural change
BP response to postural change was performed in
the same way as for the 30:15 ratio. Systolic blood
pressure (SBP) was recorded in both the supine
position and after 10–15 s of standing. The normal
response is a fall in SBP. An BPS fall 430mm of Hg
was taken as abnormal, 11–29 as borderline and
p10 as normal.11
On the basis of the responses, the patients were
categorized as follows: (i) No autonomic neuropathy:
all responses in the normal range; (ii) early auto-
nomic neuropathy: one test abnormal; (iii) definite
autonomic neuropathy: two or more abnormal tests.
Statistical analysis was done with the help of
SPSS 9.0 software for Windows and GraphPad Prism
3.0 for windows. Deviations from gaussian distribu-
tion were tested using the Kolmogorov–Smirnov
(KS) test. After ascertaining the normality, the
autonomic responses were compared between the
three groups of severity of COPD using the analysis
of variance (ANOVA). If ANOVA revealed significant
differences among groups, inter-group comparisons
were done using the Bonferroni’s test to identify
the significantly different groups. Baseline char-
acteristics in the three groups were compared
similarly. Comparisons between patients and nor-
mals, and between patients with and without
hypoxaemia were made using unpaired Student’s
t-test. Proportions of patients with normal, border-
line and abnormal responses, and absent, early and
definitive autonomic neuropathy in the three
groups of COPD were compared using the Chi-
square test. Co-efficients of correlation in bivariate
relationships were obtained using the Pearson’s
correlation test. A ‘‘P’’ value of o0.05 was
considered as statistically significant.
Results
The mean7SD age of COPD patients was
57.9679.81 while that of the normal subjects was
50.8279.82. Thirteen patients had mild, 17 had
moderate and 26 had severe COPD. The body mass
index (BMI) of patients and controls was similar
(22.4174.81 and 22.3674.45, respectively,
P40:05). The characteristics of the patients are
given in Table 1. The patients in the three groups of
COPD differed significantly for BMI, FEV1%pre-
dicted, PaO2, PaCO2, and MPAP (ANOVA). Bonferroni
test revealed patients with severe COPD to have
significantly lower BMI, FEV1%predicted, PaO2 and
higher PaCO2, and MPAP compared to mild COPD
(Po0:05 for all paired comparisons).
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Figure 1 (a) Valsalva and 30:15 ratios in patients of
COPD and normal subjects (** Po0:01; * Po0:05). (b) IE
difference (beats/min) and BP change with posture
(mmHg) in patients of COPD and normal subjects
(* Po0:05).
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Table 2 shows the frequency of normal, border-
line and abnormal responses to each of the tests of
autonomic function in patients and normal sub-
jects. Among patients, majority of the test re-
sponses were in the abnormal or borderline range
except for the 30:15 ratio for which 64% had normal
responses. The highest proportion of patients with
abnormal responses was observed for the IE
difference followed by the valsalva ratio. Among
normals, more than 90% of test responses were in
the normal or borderline range with occasional
abnormal response. Among patients, only 12
(21.4%) had no evidence of autonomic neuropathy
while 16 (28.6%) had early neuropathy and 28 (50%)
had definite neuropathy. Among normals, 7(64%)
had no evidence of autonomic neuropathy while
4(36%) had early neuropathy. No normal subject
had evidence of definite neuropathy.
The valsalva ratio, was significantly greater in
normal subjects as compared to that in the patients
with COPD ðPo0:01Þ: Similarly, the 30:15 ratio and
the IE difference was also greater in the former as
compared to the latter group ðPo0:05Þ: The BP
response to postural change was less in the former
group as compared to the latter ðPo0:05Þ: These
data are shown in Figs 1a and b.
Table 3 shows the coefficients of correlation
between FEV1% predicted, PaO2, PaCO2, TLCO; and
MPAP, and tests of autonomic function. Significant
correlations were observed between both FEV1%
predicted and PaO2, and the responses to all tests
of autonomic function except for the IE difference.
The 30:15 ratio and BP responses to posture change
also had a significant relationship with TLCO while
the valsalva ratio was also significantly related to
the MPAP.
Figure 2a shows the valsalva and 30:15 ratios in
patients with mild, moderate and severe COPD
compared using ANOVA. The valsalva ratio differed
significantly among the three groups ðPo0:01Þ:
Between-group comparisons revealed the response
in severe COPD patients to be significantly different
from both the mild and the moderate group
ðPo0:01Þ while the latter two groups did not differ
between themselves ðP40:05Þ: The 30:15 ratio was
also significantly different among the three groups
ðPo0:01Þ: Between group comparisons showed that
the severe group patients had significantly differ-
ent responses as compared to the mild group
ðPo0:05Þ; the other between-group comparisons
not being different ðP40:05Þ:
Figure 2b shows the IE difference and BP
response to postural change in patients with mild,
moderate and severe COPD compared using ANOVA.
The IE difference in the three groups was not
significantly different ðP40:05Þ: However, the BP
response to postural change was significantly
different in the three groups ðPo0:01Þ: While the
responses were not different between severe and
moderate COPD patients, both the groups had
significantly greater change in BP than that
observed in the mild group (Po0:01 and 0.05,
respectively).
Table 4 shows a comparison of responses to tests
of autonomic function in patients with and without
hypoxaemia. The differences were significant only
for the BP response to postural change ðPo0:01Þ:
Among patients with hypoxaemia, 5 (12.8%) had no
evidence of autonomic neuropathy while 10 (25.6%)
had early neuropathy and 24 (61.5%) had definite
neuropathy. Among those without hypoxaemia, 7
(41.2%) had no evidence of autonomic neuropathy
while 6 (35.3%) had early neuropathy and 4 (23.5%)
had definite neuropathy. These proportions were
significantly different ðPo0:05Þ:
Table 5 shows the responses to tests of autonomic
function according to severity of COPD. The
proportions of patients with normal, borderline
and abnormal responses were not significantly
different for Valsalva ratio and IE difference while
these were different 30:15 ratio and BP responses
to posture change. For the latter two tests, the
proportion of subjects with normal responses were
greater in those with mild COPD while borderline or
abnormal responses were more frequent in the
moderate or severe disease. Figure 3 shows the
proportions of subjects with absent, early and
definite neuropathy in different groups of COPD
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Table 3 Coefficient of correlation between physiological parameters and tests of autonomic function.
Test FEV1%predicted PaO2 PaCO2 TLCO MPAP
Valsalva ratio 0.39** 0.27* 0.22ns 0.26ns 0.33*
IE difference 0.08ns 0.06ns 0.04ns 0.11ns 0.025ns
30:15 ratio 0.31* 0.29* 0.21ns 0.36** 0.21ns
BP response to posture change 0.40** 0.34* 0.09ns 0.31* 0.14ns
** Po0:01; *Po0:05; ns: not significant, P40:05:
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severity. These proportions were significantly dif-
ferent ðPo0:05Þ:
Discussion
The present study shows that cardiovascular auto-
nomic neuropathy is common in COPD. Although it
tended to be observed more often in patients with
moderate and severe COPD, a fair proportion of
patients with mild COPD were also observed to
have this abnormality. Similarly, while it was more
prevalent in patients with hypoxaemia, it was also
found to occur in those without hypoxaemia. The
responses to tests of autonomic function had a
significant relationship with FEV1% predicted and
PaO2, but the strength of correlation was weak.
The role of hypoxaemia in the pathogenesis of
autonomic neuropathy is not clear. While Sterwart
et al.6 included only hypoxaemic subjects in their
study, our patients had a wider clinical spectrum.
An important finding in our study is that chronic
hypoxaemia is not necessary for its occurrence. The
group means differed only for the BP response to
postural change when patients with and without
hypoxaemia were compared. While definite neuro-
pathy was more frequent among those with
hypoxaemia, early/definite neuropathy was ob-
served in as many as 10 out of 17 patients without
hypoxaemia. It has been shown that administration
of oxygen does not reverse the abnormal autonomic
responses.7 This could also imply that the neurolo-
gical changes are irreversible. However, a role for
hypoxaemia cannot still be ruled out as repeated
episodes of transient hypoxaemia that may occur
during sleep, exercise or acute infective exacerba-
tions may be important. We cannot rule out such
episodes of transient hypoxaemia in our patients
without chronic hypoxaemia.
The relationship of autonomic neuropathy with
severity of COPD appears to be weak. In the study
by Stewart et al.6 the correlation coefficients were
moderately strong only between Valsalva ratio and
PaO2 (0.66), Valsalva ratio and FEV1 (0.56), 30:15
ratio and PaO2 (0.51) and 30:15 ratio and FEV1
(0.51). The correlations between other tests and
FEV1 or PaO2 were weak or nonsignificant. In the
present study with patients having a wider clinical
spectrum, these correlations were also weak.
Except for the IE difference, the other tests showed
significantly greater changes from the normal range
in patients with moderate or severe disease as
compared to those with mild COPD. The propor-
tions of patients with normal, borderline and
abnormal responses were not significantly different
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Figure 2 (a) Valsalva and 30:15 ratios in patients of
COPD according to severity (ANOVA ** Po0:01). (b) IE
difference (beats/min) and BP change with posture (mm
Hg) in patients of COPD according to severity (ANOVA
**Po0:01; ns: P40:05).
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for the Valsalva ratio and IE difference between the
three groups of clinical severity while for 30:15
ratio and BP responses to posture change, the
proportion of subjects with normal responses were
greater in those with mild COPD while borderline or
abnormal responses were more frequent in the
moderate or severe disease. These results suggest
that although abnormalities are more likely to be
observed in those with moderate or severe disease,
these may also be found in those with mild COPD.
This coupled with the observation of abnormal
responses in patients without chronic hypoxaemia
suggest that autonomic neuropathy may be an early
phenomenon in the natural history of COPD.
Our results suggest that autonomic neuropathy in
COPD has no causative relationship with the
severity of airway obstruction and hypoxaemia
but is an independent abnormality that develops
gradually and progressively and thus runs parallel
with other markers of disease severity. This would
also explain the weak but significant correlations
observed between TLCO; MPAP and the responses to
some of the tests of autonomic function. The
abnormality in the reflexes used to assess cardio-
vascular autonomic responses could lie in the
receptors, the afferent pathway, the center, the
efferent pathway or the effector organ. This
requires investigation.
The clinical significance of these observations
and the previous documentation of autonomic
neuropathy is that it may carry a grave prognosis
as in diabetes mellitus12 putting the subject at the
risk of sudden cardiac death. Tentolouris et al.13
have shown that QTc prolongation is associated
with major degrees of autonomic neuropathy in
diabetics. Stewart et al.6 have also postulated a
role for autonomic dysfunction in the salt and
water retention in COPD. Although none of our
patient complained of symptoms that could arise
because of autonomic dysfunction, symptoms such
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Table 4 Comparison of responses to tests of autonomic function between patients with and without
hypoxaemia.
Test PaO2480mmHg ðn ¼ 17Þ PaO2o80mm Hg ðn ¼ 39Þ
Valsalva rations 1.2470.17 1.1570.18
IE differencens 11.5376.06 10.0874.95
30:15 rations 1.0870.07 1.0570.05
BP responses to posture change** 17.3577.20 24.4178.76
** Po0:01; ns: not significant, P40:05:
Table 5 Frequency of different responses to tests of autonomic function according to severity of COPD.
Test Mild ðn ¼ 13Þ Moderate ðn ¼ 17Þ Severe ðn ¼ 26Þ
Valsalva rations
Normal 7 (53.8) 9 (52.9) 6 (23.1)
Borderline 2 (15.4) 3 (17.6) 3 (11.5)
Abnormal 4 (30.8) 5 (29.4) 17 (65.4)
IE differencens
Normal 3 (23.1) 4 (23.5) 6 (23.1)
Borderline 3 (23.1) 5 (29.4) 3 (11.5)
Abnormal 7 (53.8) 8 (47.1) 17 (65.4)
30:15 ratio**
Normal 12 (92.3) 14 (82.4) 10 (38.5)
Borderline 0 0 2 (7.7)
Abnormal 1 (7.7) 3 (17.6) 14 (53.8)
BP response to posture change**
Normal 7 (53.8) 5 (29.4) 0
Borderline 5 (38.5) 4 (23.5) 15 (57.7)
Abnormal 1 (7.7) 8 (47.1) 11 (42.3)
Figures in parenthesis are column percentages. **Po0:01; *Po0:05; ns: not significant, P40:05:
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as giddiness or palpitations that some patients of
COPD do complain of or the occurrence of
arrythmias may have a basis in this.
We excluded other possible causes of neuropathy
in our patients, clinically or by biochemical tests
where relevant. Patients with diabetes mellitus,
renal failure, carcinoma, connective tissue disor-
ders and liver disease were excluded. None of the
patients consumed alcohol on a regular basis or had
any dietary deficiency of vitamins (B group) or any
disease such as malabsorption that could cause
vitamin deficiency. The body mass was similar to
the control group. Thus, we are certain that the
observed changes in autonomic function were due
to COPD itself.
In conclusion, cardiovascular autonomic neuro-
pathy is common in COPD and should be documen-
ted. Its pathogenesis, clinical significance and
natural history remain to be established.
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Figure 3 Proportions of subjects with absent, early and
definite neuropathy in groups of COPD according to
severity.
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